BACKGROUND: The objective of this study was to evaluate the efficacy and toxicity of combination chemotherapy with gemcitabine and paclitaxel as a second-line regimen in patients with advanced urothelial carcinoma. METHODS: Twenty patients with advanced urothelial carcinoma who were resistant to an M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy regimen were administered chemotherapy consisting of intravenous gemcitabine 2500 mg/m(2) and paclitaxel 150 mg/m(2) (GP) every 2 or 3 weeks. RESULTS: The patients received a median of 7.7 cycles of treatment (range, 2-20 cycles). Six of the 20 patients (30%; 95% confidence interval [CI], 10%-50%) had a major response to treatment (a complete response [CR] in 5% and a partial response [PR] in 25%). Seven patients (35%) had stable disease (SD). The median duration of response was 4.5 months (range, 1-9 months) and the disease control rate (CR + PR + SD) was 65%. The median survival was 11.5 months (range, 2-22 months) and the 1-year survival rate was 35%. The patients tolerated this regimen well, with only grade 3-4 neutropenia being observed in 6 patients (30%), anemia in 3 (15%), and thrombocytopenia in 1 (5%). The response rate to M-VAC in the first-line chemotherapy was significantly associated with the response to GP as the second-line chemotherapy. CONCLUSION: The combination of gemcitabine and paclitaxel is active and well tolerated as a second-line treatment in patients with advanced urothelial carcinoma.
BACKGROUND: The objective of this study was to evaluate the efficacy and toxicity of combination chemotherapy with gemcitabine and paclitaxel as a second-line regimen in patients with advanced urothelial carcinoma. METHODS: Twenty patients with advanced urothelial carcinoma who were resistant to an M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy regimen were administered chemotherapy consisting of intravenous gemcitabine 2500 mg/m(2) and paclitaxel 150 mg/m(2) (GP) every 2 or 3 weeks. RESULTS: The patients received a median of 7.7 cycles of treatment (range, 2-20 cycles). Six of the 20 patients (30%; 95% confidence interval [CI], 10%-50%) had a major response to treatment (a complete response [CR] in 5% and a partial response [PR] in 25%). Seven patients (35%) had stable disease (SD). The median duration of response was 4.5 months (range, 1-9 months) and the disease control rate (CR + PR + SD) was 65%. The median survival was 11.5 months (range, 2-22 months) and the 1-year survival rate was 35%. The patients tolerated this regimen well, with only grade 3-4 neutropenia being observed in 6 patients (30%), anemia in 3 (15%), and thrombocytopenia in 1 (5%). The response rate to M-VAC in the first-line chemotherapy was significantly associated with the response to GP as the second-line chemotherapy. CONCLUSION: The combination of gemcitabine and paclitaxel is active and well tolerated as a second-line treatment in patients with advanced urothelial carcinoma.
Authors: Jinxing Li; Beth Juliar; Constantin Yiannoutsos; Rafat Ansari; Edward Fox; Michael J Fisch; Lawrence H Einhorn; Christopher J Sweeney Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: S B Saxman; K J Propert; L H Einhorn; E D Crawford; I Tannock; D Raghavan; P J Loehrer; D Trump Journal: J Clin Oncol Date: 1997-07 Impact factor: 44.544
Authors: John D Hainsworth; Anthony A Meluch; Sharlene Litchy; Frederick M Schnell; James D Bearden; Kathleen Yost; F Anthony Greco Journal: Cancer Date: 2005-06-01 Impact factor: 6.860
Authors: V Lorusso; C F Pollera; M Antimi; G Luporini; C Gridelli; G L Frassineti; C Oliva; M Pacini; M De Lena Journal: Eur J Cancer Date: 1998-07 Impact factor: 9.162
Authors: Donald S Kaufman; Michael A Carducci; Tim M Kuzel; Mary B Todd; William K Oh; Matthew R Smith; Zhishen Ye; Steven J Nicol; Walter M Stadler Journal: Urol Oncol Date: 2004 Sep-Oct Impact factor: 3.498
Authors: B J Roth; R Dreicer; L H Einhorn; D Neuberg; D H Johnson; J L Smith; G R Hudes; S M Schultz; P J Loehrer Journal: J Clin Oncol Date: 1994-11 Impact factor: 44.544